09/14/2026
BREAKTHROUGH FOR HPV-UNRELATED HEAD AND NECK SQUAMOUS CELL CARCINOMA
No more options after chemo and immunotherapy? A new bispecific antibody is changing the game for HPV-unrelated head and neck cancer.
Patients with HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) often face rapid progression and very limited options after platinum-based chemotherapy and PD inhibitors. This group represents ∼75% of all cases and has the poorest prognosis.
New hope from ASCO 2026:
amivantamab.
Amivantamab is a first-in-class fully-human bispecific antibody.
The designation is supported by the OrigAMI-4 study - an international trial in 11 countries presented at ASCO Chicago:
In 102 heavily pretreated patients, treatment led to tumor reduction or disappearance in 43 patients: 28 with significant tumor shrinkage and 15 with complete disappearance.
What’s next:
The ongoing Phase 3 OrigAMI-5 (NCT07276399) is now testing subcutaneous amivantamab + pembrolizumab + carboplatin vs. standard 5FU + pembrolizumab + platinum as first-line therapy for HPV-unrelated R/M HNSCC.
Source: Johnson & Johnson / FDA announcement + OrigAMI-4 data ASCO 2026
Read more: morningstar.com